SAN ANTONIO CANCER INSTITUTE

圣安东尼奥癌症研究所

• 批准号: 6842190
• 负责人: DAVID H BOLDT
• 金额: $ 104.08万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-19 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6842190
• 关键词: biomedical facility; clinical research; neoplasm /cancer

DESCRIPTION (provided by applicant): The San Antonio Cancer Institute (SACI) represents the combined cancer research programs of a private, not-forprofit institution, the Cancer Therapy and Research Center (CTRC), and a state-supported academic medical center, The University of Texas Health Science Center at San Antonio (UTHSCSA). Since the inception of the CTRC in 1972 and its dedication in 1974, the two institutions have had a long and successful history of collaboration in cancer treatment and cancer research. The UTHSCSA brings significant attributes to the partnership, including its reputation as an outstanding academic institution, strong and diverse programs in the basic sciences, and equally strong clinical research capabilities. The UTHSCSA provides the facilities and faculty to train new cancer research investigators, particularly those interested in translational research. The CTRC contributes comprehensive outpatient cancer treatment, outreach, and education capabilities to the partnership. This nationally known treatment center registers more than 100,000 patient visits annually. The CTRC also includes the Institute for Drug Development as one of its subsidiaries. This world-class anticancer drug development organization is the largest such program capable of taking new anticancer agents through "first-in-man" (phase I) clinical testing and into early safety and efficacy trials (phase II). The seven research programs presented for review in this application include: Cancer Metastasis, Cancer Prevention and Health Promotion, DNA Repair and Tumor Suppressor Genes, Experimental Therapeutics, Prostate Cancer, Geriatric Oncology, Signal Transduction and Macromolecular Interaction. SACI members have access to fourteen proposed Shared Resources that provide technology and expertise to enhance research productivity and scientific collaborations within the Institute. The SACI Shared Resources presented for approval in this application include the following: Antigen and Antibody Production, Biostatistics and Medical Informatics, Clinical Protocol and Data Management, Cytogenetics and Genetics Resource, Flow Cytometry, Genetic Mouse Models, Laboratory Animal Resources, Macromolecular Structure, Mass Spectrometry, Microarray, Optical Imaging, Pathology, Pharmacology, and Protein-Protein Interactions. Three programs are targeted for development over the next five years: our emerging programs in pediatric oncology and gastrointestinal malignancies, and a new Molecular Therapeutics Program that will expand SACI?s medicinal chemistry and high throughput screening capabilities, and facilitate the in-house discovery of new anticancer agents that will be fed into SACI?s drug pipeline-from identification of the molecular target to screening, chemistry, formulation, testing in animal models, toxicology, and, ultimately, to testing in humans.

描述（由申请人提供）：圣安东尼奥癌症研究所 （SACI）代表私人，非营利组织的癌症研究计划 机构，癌症治疗与研究中心（CTRC）和A 德克萨斯大学卫生大学国家支持的学术医学中心 圣安东尼奥（UTHSCSA）的科学中心。自从CTRC成立以来 1972年及其在1974年的奉献精神，这两个机构有很长的 癌症治疗和癌症研究的成功历史。 UTHSCSA为合作伙伴关系带来了重要的属性 作为杰出学术机构，强大而多样的计划的声誉 在基本科学和同样强大的临床研究能力中。这 UTHSCSA提供了培训新癌症研究的设施和教师 调查人员，特别是那些对转化研究感兴趣的人。这 CTRC贡献了全面的门诊癌症治疗，外展和 伙伴关系的教育能力。这种全国已知的待遇 中心每年注册100,000多个患者访问。 CTRC也是如此 包括药物开发研究所是其子公司之一。这 世界一流的抗癌药物开发组织是最大的这样的 能够通过“人类”来吸引新的抗癌代理的程序（阶段 i）进行临床测试以及早期安全和效力试验（II阶段）。这 在本申请中提出的七个研究计划包括： 癌症转移，预防癌症和健康促进，DNA修复和 肿瘤抑制基因，实验治疗，前列腺癌，老年病 肿瘤学，信号转导和大分子相互作用。 SACI成员 可以访问提供技术和技术的14个共享资源 提高研究生产力和科学合作的专业知识 在研究所内。 SACI共享资源供批准 该应用程序包括以下内容：抗原和抗体产生， 生物统计学和医学信息学，临床方案和数据管理， 细胞遗传学和遗传学资源，流式细胞术，遗传小鼠模型， 实验室动物资源，大分子结构，质谱法， 微阵列，光学成像，病理学，药理学和蛋白质 - 蛋白质 互动。在接下来的五个中，三个计划的发展目标 年：我们在小儿肿瘤学和胃肠道领域的新兴计划 恶性肿瘤和一种新的分子治疗计划，可以扩大saci？ 药物化学和高通量筛查能力，并促进 内部发现的新抗癌剂将被送入Saci？ 从鉴定分子靶标的药物管道到筛选， 化学，配方，动物模型中的测试，毒理学以及最终 在人类中进行测试。